PROVENGE

Shares of biotech firm Dendreon (NASDAQ: DNDN) have plunged on Wednesday after Bank of America Merrill Lynch downgraded the stock from Neutral to Underperform. The analysts titled the report, "Not comfortable short term or long term," sending shares skidding more than 6% in mid-day trade. In...

Deutsche Bank has published a research report on Dendreon (NASDAQ: DNDN) after the company reported $82M in Provenge sales during 4Q and is trading up ~50% today since market open. In the report, Deutsche Bank writes, "DNDN just reported $82M in 4Q11 Provenge sales, AHEAD of Street consensus of ~$...

The big story in Wednesday's after hours trading session is the annihilation of one-time biotech darling Dendreon (NASDAQ: DNDN) after the company reported its second quarter earnings results. It didn't go so well...the stock is down 62% in late trading! No one wants to see this (except the shorts...

Dendreon Corporation (NASDAQ: DNDN) shares are spiking 2.3% on news that the FDA has approved its use for a New Jersey plant to manufacture its drug Provenge, which is used for prostate cancer. "PROVENGE has the largest reported survival benefit in patients with asymptomatic or minimally...

Shares of Dendreon Corp. (NASDAQ: DNDN) are popping this morning; currently, the stock is up over 9.50%, trading at $37.05. The company said yesterday that initial sales for its prostate cancer treatment, Provenge, totaled $2.8 million in the second quarter. They also reported that sales are...

Shares of Dendreon Corp. (NASDAQ: DNDN) ended the session off 3.75%, trading at $32.33, but have since cratered in the after-hours trade. The biotechnology company is currently trading at $27.00, off another 16.50%. Dow Jones is reporting that Medicare is probing into their “coverage” of Provenge...